Adaptive Biotechnologies Corporation

Equities

ADPT

US00650F1093

Biotechnology & Medical Research

Delayed Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
3.21 USD +11.07% Intraday chart for Adaptive Biotechnologies Corporation -3.60% -34.49%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
JPMorgan Adjusts Price Target on Adaptive Biotechnologies to $8 From $11, Maintains Overweight Rating MT
Adaptive Biotechnologies' Q4 Loss Widens; Revenue Declines; Shares Down MT
Transcript : Adaptive Biotechnologies Corporation, Q4 2023 Earnings Call, Feb 14, 2024
Earnings Flash (ADPT) ADAPTIVE BIOTECHNOLOGIES Reports Q4 Revenue $45.8M, vs. Street Est of $48.5M MT
Adaptive Biotechnologies Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Transcript : Adaptive Biotechnologies Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 01:30 PM
Adaptive Biotechnologies Corporation and Collaborators to Present More Than 30 Abstracts Demonstrating the Actionability of ClonoSEQ MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th Annual Meeting CI
Adaptive Biotechnologies Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Adaptive Biotechnologies Corporation, Q3 2023 Earnings Call, Nov 09, 2023
Earnings Flash (ADPT) ADAPTIVE BIOTECHNOLOGIES Reports Q3 Revenue $37.9M, vs. Street Est of $43M MT
Adaptive Biotechnologies Corporation Updates Revenue Guidance for the Full Year 2023 CI
Adaptive Biotechnologies Partners With BeiGene on Minimal Residual Disease Testing of Potential Treatments for Lymphoid Malignancies MT
Adaptive Biotechnologies Corporation Announces New Translational Collaboration to Measure Minimal Residual Disease with Clonoseq(R) Assay Across Beigene's Lymphoid Malignancy Pipeline CI
Morgan Stanley Cuts Adaptive Biotechnologies' Price Target to $10 From $13, Keeps Equalweight Rating MT
BofA Securities Trims Price Target on Adaptive Biotechnologies to $9 From $11, Maintains Buy Rating MT
Transcript : Adaptive Biotechnologies Corporation Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-13-2023 01:35 PM
Adaptive Biotechnologies Corporation Announces Launch of Epic Integration for ClonosEQ CI
Adaptive Biotechnologies Corporation Announces Kevin Conroy Resigns from the Board CI
Insider Sell: Adaptive Biotechnologies MT
Adaptive Biotechnologies Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Transcript : Adaptive Biotechnologies Corporation, Q2 2023 Earnings Call, Aug 02, 2023
Earnings Flash (ADPT) ADAPTIVE BIOTECHNOLOGIES Posts Q2 Revenue $48.9M, vs. Street Est of $44.9M MT
Adaptive Biotechnologies Corporation Announces Executive Changes CI
Adaptive Biotechnologies Corporation Reiterates Revenue Guidance for the Full Year 2023 CI
Insider Sell: Adaptive Biotechnologies MT
Chart Adaptive Biotechnologies Corporation
More charts
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its proprietary technologies to read the diverse genetic code of a patient’s immune system and understand precisely how the immune system detects and treats disease in that patient. It has business around two main areas: clinical assessment of minimal residual disease (MRD) in lymphoid malignancies and immune medicine (IM)-driven drug discovery and development. The MRD business focuses on the use of its highly sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. It comprises its clonoSEQ clinical diagnostic test, offered to clinicians, and its clonoSEQ assay, offered to biopharmaceutical partners, to advance drug development efforts (MRD Pharma).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
3.21 USD
Average target price
6.833 USD
Spread / Average Target
+112.88%
Consensus
  1. Stock
  2. Equities
  3. Stock Adaptive Biotechnologies Corporation - Nasdaq
  4. News Adaptive Biotechnologies Corporation
  5. Adaptive Biotechnologies : Morgan Stanley Adjusts Adaptive Biotechnologies PT to $46 From $42, Maintains Equal Weight Rating